Introduction {#sec1}
============

Coronavirus disease 2019 (COVID-19) has caused catastrophic pandemics since late 2019, with clinical features from asymptomatic infection to multiorgan failure owing to cytokine storm. Until now, there are no approved treatments against COVID-19, while many drugs have been hypothesized to be active via antiviral or anti-inflammatory effect.[@bib1] Hydroxychloroquine (HCQ) was theoretically to be actively against SARS-CoV-2 via interfering with the glycosylation of ACE2, blocking virus/cell fusion and inhibiting lysosomal activity by increasing intracellular pH level, and have anti-inflammatory effect by inhibiting the production and release of TNF and IL-6.[@bib2] Animal studies had demonstrated HCQ can efficiently inhibit SARS-CoV-2 infection in vitro, along with its anti-inflammatory function.[@bib3] However, a previous retrospective study revealed that treatment with hydroxychloroquine, azithromycin, or both was not associated with significantly lower in-hospital mortality among COVID-19 patients.[@bib4] Until now, efficacy of HCQ against SARS-CoV-2 infection remained debating. Besides, associated discussion of viral load kinetics after HCQ treatment is rare. Here we present six patients of mild to moderate COVID-19, with comprehensive virology and cytokine data.

Material & methods {#sec2}
==================

Between January 2020 and April 2020, there were 17 confirmed cases of COVID-19 hospitalized at National Taiwan University Hospital. They were confirmed through reverse transcription-polymerase chain reaction (RT-PCR) test of SARS-CoV-2 envelope (E), nucleocapsid (N), and RNA-dependent RNA polymerase (RdRp) gene. Six of them were prescribed with HCQ upon admission, with a loading dose of 400 mg twice daily for the first seven days, and followed by 200 mg twice daily for another seven days. Azithromycin was not given due to potential cardiac toxicity in the context of co-administration with HCQ.

During hospitalization, blood tests for hemogram, C-reactive protein, ferritin were checked twice per week, including the period of HCQ treatment. Cytokine profile was checked before HCQ initiation and on the 14th day of HCQ treatment. Chest radiograph were arranged once per week. Sputum, nasal swab and throat swab specimens were collected for examinations of SARS-CoV-2 RT-PCR every other day. Plasmid DNA containing the SARS-CoV-2 targeted E gene, was used to construct the standard curve to estimate the SARS-CoV-2 viral load by real-time RT-PCR tests.

Results {#sec3}
=======

The demographic features of the patients are presented in the Table (See [Table 1](#tbl1){ref-type="table"} ). Most of them were young female. All patients had mild respiratory symptoms before admission. None of them had respiratory distress. Initially, no leukocytosis or elevated C-reactive protein level was noted. At presentation, only one patient (Case 1) had fever (38.3 °C) with chills, and her chest radiography revealed increasing infiltration over bilateral lung fields. The other five patients had normal chest X-ray image upon admission. Fever and airway symptoms of all six patients resolved within a week after admission. No new subjective discomfort, including nausea, abdominal pain, diarrhea or palpitation, was complained during HCQ therapy. All patients were discharged without complication after three consecutive sets of negative RT-PCR results from sputum, nasal swab and throat swab specimens.Table 1Demographics, clinical features at admission, treatment, and outcomes of the patients.Table 1Case 1Case 2Case 3Case 4Case 5Case 6**Demographics**Age (years)265837222923GenderFemaleMaleFemaleFemaleFemaleFemaleComorbiditiesChronic urticariaHypertensionAllergic rhinitisAllergic rhinitis**Clinical features on admission**Duration of symptoms before admission (days)38931430Clinical featuresFever, chills, sore throat, malaisesore throat, dry cough, cervical lymphadenopathydry cough, malaise, rhinorrhea, dyspnearhinorrheasore throat, malaise, productive cough, nausea, vomiting, diarrhealoss of smell and taste, rhinorrheaDiagnosisPneumoniaURIURIURIURIURI**Symptoms and vital signs** Temperature (°C)38.336.33736.336.436 Heart rate (/min)866694787884 Respiratory rate (/min)201815202020 Blood pressure (mmHg)120/78149/92133/72123/68104/80122/79 O2 saturation in ambient air1009998100100100**Laboratory results** Hb (g/dL)10.91512.51412.912 WBC (cells/μL)523039606150250079506910 Lym (%)21.439.91239.628.624.9 Platelet (K/μL)310160214225282288 CRP (mg/dL)0.170.110.150.020.170.02 ALT (U/L)733171388 LDH (U/L)151169145190134131 CK (U/L)3116245472958 Ferritin (ng/mL)5.85459.4442.5872.74138.113.76Viral load from throat swab specimens (copies/mL)12,4911,308,3092,843,26425900Days of SARS-CoV-2 IgG detection after symptom onset (days)171428NA14[a](#tbl1fna){ref-type="table-fn"}30[a](#tbl1fna){ref-type="table-fn"}**Cytokine profile (pg/mL)**IL-17Day 00000114.740Day 145.83032.390.0215.321.46IFN-γDay 0000000Day 140000.2100.06TNFDay 000000.140Day 14000000IL-10Day 00.820.040.6100.650Day 140.390.780.490.280.360.45IL-6Day 02.842.8401.65.20Day 1402.430.240.2901.89IL-4Day 00.1600000Day 1400.1302.2400IL-2Day 00000.270.270Day 1400.3100.5100**Treatment and outcomes**Duration from symptom onset to last detectable viral load (days)473833162546Length of hospital stay (days)523528222024OutcomesSurvivedSurvivedSurvivedSurvivedSurvivedSurvived[^2][^3]

Virology data from upper and lower airway specimens are presented in [Fig. 1](#fig1){ref-type="fig"} . Those with more serious symptoms and admitted in the early stage of clinical symptoms tend to have higher viral loads of sputum specimens (Case 1--3, \>10^5^ copies/mL), compared with those who were admitted in their late stage of infection (Case 4--6, \<10^3^ copies/mL). Of Case 1, 2 and 3, viral load from upper airway specimens showed a decrease of 2 logs or more within seven days after starting HCQ treatment. Among the six patients, the mean duration from symptom onset to last detectable viral load was 34 ± 12 days.Fig. 1Viral load kinetics from respiratory specimens of throat swab (A) and sputum (B).Fig. 1

All six patients were found to have extremely low titers of interferon-gamma (IFN-γ) upon admission and on the 14th day of HCQ therapy. Most of the cytokines we checked upon admission were in low titers or undetectable; except for Case 5, who was admitted 14 days after initial symptom onset and was found to have a high IL-17 level. Three of the six patients were found to have mildly elevated IL-17 level after 14-day HCQ treatment. Mild elevated IL-6 level was observed in four of six patients upon their admission, and all patients had low level or undetectable IL-6 after HCQ treatment.

Discussion {#sec4}
==========

Until now, the efficacy of HCQ for treating COVID-19 remained controversial. A retrospective study by Rosenberg ES et al. revealed that treatment with hydroxychloroquine, azithromycin, or both was not associated with lower in-hospital mortality among COVID-19 patients. An open-label, randomized controlled trial of 150 patients with mild to moderate disease, also demonstrated that the use of HCQ did not show significant difference in negative conversion of SARS-CoV-2 by 28 days compared with standard of care.[@bib5] Besides, a randomized trial by Boulware et al. also revealed HCQ did not prevent illness compatible with Covid-19 or confirmed infection when used as post-exposure prophylaxis within four days after exposure.[@bib6] However, whether HCQ is able to prevent SARS-CoV-2 infection as pre-exposure prophylaxis remained uncertain.

Our study echoes the finding that the administration of HCQ is not associated with acceleration of virus clearance. Among our patients, three with initial higher viral load showed a decrease of 2 logs or more in their viral loads within seven days after starting HCQ treatment, which was similar to previous reports of patients without any antiviral or antiinflammation medications.[@bib7] ^,^ [@bib8]

Among our cases, three of them had elevation of IL-17 level, which was considered as an essential role in several inflammatory respiratory diseases. The reported cases demonstrated that the elevation of IL-17 was observed even in patients with only mild disease of COVID-19. Casillo et al. thus hypothesized IL-17 as a potential therapeutic target.[@bib9] Previous reports revealed that HCQ inhibits the differentiation of Th-17 cells and decreased the release of IL-17 from the experience of treating systemic lupus erythematosus.[@bib10] Early administration of HCQ among our patients might inhibit the cytokine release and thus prevent hyperinflammation events, which potentially leads to deteriorating clinical condition. Nevertheless, the impact of HCQ on cytokine kinetics in COVID-19 patients still needs further studies.

In addition, low level of interferon-gamma was noted in our patients of different stages of infection, which implied atypical immune response against SARS-CoV-2 infection. Previous reports revealed that SARS-CoV-2 replicates stealthily in host cells without detectably triggering type I and III interferon, leading to high viral loads and impaired control for inflammation.[@bib11] Our study demonstrated the immune response was impaired not only found in type I and III interferon, but also found in type II interferon.

Our case series demonstrated our experience of HCQ use in patients with mild to moderate COVID-19. Prolonged virus shedding is still observed regardless of HCQ. The impact of HCQ on cytokine kinetics remained unclear; however, IL-17 could be an inflammatory marker for disease status monitor and a potential therapeutic target. The impact on clinical course, viral shedding and cytokine kinetics still needs further investigation.

Declaration of Competing Interest
=================================

none to declare.

This study is supported by National Taiwan University Hospital TOP DOWN Project (NO. 109-P13 and NO. 109-P14).

[^1]: These authors contributed equally to this paper.

[^2]: **Abbreviation:** URI, upper respiratory infection; Hb, hemoglobulin; Lym, lymphocyte; CRP, C-Reactive protein; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; CK, creatine kinase; IL, interleukin; IFN-γ, interferon gamma; TNF, tumor necrosis factor.

[^3]: SARS-CoV-2 specific IgG could be detected from the serum sampled upon admission.
